Researchers studied 1,453 infants and found that the incidence of medically attended respiratory syncytial virus-associated lower respiratory tract infection was 70.1% lower in those who received nirsevimab prophylaxis, compared with the placebo group. The findings in The New England Journal of Medicine also showed that the incidence of hospitalization for RSV-associated lower respiratory tract infection was 78.4% lower in the nirsevimab group, compared with controls.
Nirsevimab may lower pediatric RSV risk, hospitalization
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.